Overview
In preparation to list Med-X, Inc. shares on a public exchange, the management team has reserved the Nasdaq ticker symbol, (MXRX).
Recently the Company secured a $100 million capital commitment from Global Emerging Markets, a Luxembourg-based alternative investment group worth $3.4 billion. The investment banking community has recognized the continued demand for the Med-X product selection as well as large investor demand to participate in investment strategies that make an impact on health and ecology. The company investor base has surpassed 3,800 stakeholders which has supported the Company’s mission since inception. Now that the Company has secured large scale capital to advance the business model, management is negotiating with investment banking community players to Underwrite and Initial Public Offering.
Now you can join the Green Scene movement that is making a difference in the areas of Health, Wellness and Ecology everyday, while management prepares the Company for expansion. This round of Regulation A+ crowdfunding will continue to support revenue growth of its brand portfolio, develop exciting new products and pursue acquisition opportunities, as the Company continues to draw awareness of the overuse of toxic synthetic chemicals and addictive pharmaceutical products.
YEAR FOUNDED
2014
RAISED TO DATE
$10M+
INVESTORS
3800+
MODEL
Portfolio
CURRENT PRICE PER SHARE
$.80
CURRENT MINIMUM INVESTMENT
$420
INDUSTRY
Pest Control, Healthcare, Emerging
PATH TO LIQUIDITY
IPO
Millions of Pounds of Pesticides
Continue to be Sprayed Each Year
Historically, the pest management industry has been controlled by a small group of very large and powerful international chemical corporations. These corporations hold patents and spend millions of dollars lobbying governments all over the world to make sure their synthetic pesticides are deemed “safe for use”, even though the long-term effects from exposure have been proven to be unhealthful and dangerous.
Most of these synthetic pesticides contain strong toxic/poisonous chemicals with proven long-lasting, devastating carcinogenic effects. These compounds can take generations to become nascent in the environment. As more chemicals are sprayed or used in products, the resulting pollution compounds to increasingly harm people and the environment.
Chemicals from plastics and pesticides are now beginning to be found in our groundwater and public drinking water supplies for the first time. No wonder numerous studies are now linking diseases such as Parkinson’s disease, asthma, cancer and reproductive dysfunction to chemical pesticides.
Source: https://www.usgs.gov/centers/oki-water/science/pesticides?qt-science_center_objects=0#qt-science_center_objects
We all know a family impacted by the Opioid Epidemic. For years, pharmaceutical conglomerates have lobbied for lower thresholds on drug regulation, knowing full well the addictive nature of opioids. These addictive drugs have been marketed for the use of everyday pain relief, even though science clearly proves the addictive nature of the chemicals used to make them. For a person born in 2017 the odds of dying from an opioid overdose is now higher than dying in a car accident.
Source: https://www.drugabuse.gov/drug-topics/opioids/opioid-overdose-crisis
29% OF ALL PEOPLE WHO ARE PRESCRIBED OPIOIDS END UP MISUSING THEM AND 12% OF ALL PEOPLE PRESCRIBED OPIOIDS BECOME ADDICTED
The Med-X Solution
Med-X, Inc. has developed multiple all-natural plant-based brands of products that solve the same everyday issues people have been trying to solve with chemicals. Med-X is able to sell these products into the homes of everyday Americans through our partnerships with major retail and healthcare distributors as well as the leading international professional pest control distributors. The company is constantly marketing and educating the public about the dangers we face while at the same time offering real, proven effective, safe solutions.
Through targeted marketing, national and international distribution venues and exposure through our media divisions, our high margin proprietary products are cutting through the noise and getting mainstream attention and sell-through. Med-X is also on the cutting edge of green product development by introducing new innovative topical and supplement products, which will also become available to consumers in the future.
Our Mission
We would love to tell you that our green solution products and services will bring down Big Chemical and Big Pharma., but let’s be real - that is not going to happen. The point of this mission, in fact, is more about balance, transparency, and responsibility. Our goal here is to simply offer alternatives in markets that frankly have never been embraced as safe and effective natural options. And as you are aware, our thinking and products are beginning to resonate.
Safe Is The New Normal
We are at the forefront of providing safer alternatives to Big Chemical and Big Pharma that will make them more accountable. The consumer is demanding it. Times have changed. If you can offer a person the choice between a green solution and a chemical one, most Americans will now choose the green option, so long as it offers similar results. In recent surveys It’s proven that most Americans will actually pay substantially more for a safer option.
Thankfully, the products Med-X produces fall in line with middle America values. The company has sourced product ingredients and focused on low-cost manufacturing techniques that enable us to offer these products at favorable costs to consumers, while holding higher margins for stakeholders.
In the past, there were little or no options for a homeowner to choose an effective green pesticide to be used in their home. Likewise, there were limited safe, drug-free options for truly relieving a migraine headache or everyday chronic pain. Now there are multiple options being offered by our Med-X Divisions and more that are in final development by Med-X scientists, doctors, and formulators. These products are proven effective in clinical trials and many are already in national and international distribution channels with sell-through driving growth.
Source: https://www.surveymonkey.com/stories/SM-366ZZGPJ/
Our Brands
Med-X has built a portfolio of high margin commercial and consumer product brands as well as professional pest control service products. These proven brands help drive the company’s current revenue. This portfolio strategy gives the company the flexibility and power to scale up operations and raise revenues in any sector by acquiring other like-minded brands who want the opportunity to grow alongside us. The company is already in talks with several small to medium-sized companies who have shown interest in being a part of a bigger green movement.
-1.png?width=318&name=image%20(1)-1.png)
The entire Nature-Cide line of products has 10 years of research and development behind it. All of these products have been proven effective in the field by licensed pest management professionals as well as third party laboratory efficacy tests. These products are currently being used nationwide in mainstream professional and “Do it Yourself” pest control, hospitality and agriculture.
Thermal-Aid products use clinically proven and are a patented all-natural therapeutic heating/cooling modality designed explicitly for the medical field, to reduce swelling and relieve various pain issues. Thermal-Aid products cover a wide variety of needs for patients in all age groups for a gamut of ailments including but not limited to arthritis, fibromyalgia, multiple sclerosis, migraines, back pain, and muscle aches. Thermal-Aid products can be found in various OTC pharmacy outlets and qualify for patient insurance reimbursement and FSA programs throughout the United States.
Malibu Brands is a premium, homeopathic lifestyle brand. Malibu Brands' first product is the Pacific Pain Relief Cream, which is a proven, natural topical analgesic cream for the temporary relief of various pains including arthritis, joint pain, muscle aches, headaches, and migraines. Malibu Brands is working to expand its product footprint with multiple products in development including a pain cream that utilizes plants as an ingredient. Additionally, the Malibu Brands division is a southern California lifestyle brand with a planned expansion from pain management and supplements to embarking on designing a unique clothing line that uses alternative sustainable materials such as plant fiber, link hemp and bamboo as they become readily available.
The National Investor Network is a hub for everyday investors to gather resources and information in regards to companies raising capital using public or private equity. It serves as a portal with an extensive information base of companies and executives who are publicly raising capital or trading securities. This venue will be positioned to assist Med-X and other private and public companies with information dissemination to assist in their pursuits.
Product Positioning
National Pest Control And Healthcare Distribution
Nature-Cide is being used by a growing network of commercial customers including licensed commercial and residential pest control operators throughout the United States and beyond. Nature-Cide currently enjoys solid relations with the largest pest, turf and janitorial suppliers such as Target Specialty Products, Veseris here in the USA with new relations with Rentokil Initial in various regions including Asia and India.
The company plans to continue aggressively marketing within the Pest Control, Hospitality, Transportation, Agriculture, and Janitorial supply markets, while also pursuing the implementation of Nature-Cide products being used in state and federal facilities throughout various regions of the United States.
Our Team
Matthew A. Mills
Matthew Mills is the Med-X, Inc. CEO and Chairman of the Board. Matthew is the Company’s visionary. He leverages his vast experience and knowledge in product development, operations, business development, manufacturing, marketing, and crowdfunding to position the company for short-term and long-term growth.
Dr. David Toomey
Dr. David Toomey has spent his professional life as a family physician for more than 24 years and as a Hospice Medical Director for the last decade. Over his many years as a physician, Dr. Toomey has also worked as a clinical investigator, developing and running clinical trials for multiple companies, including major pharmaceutical firms.
Ronald J. Tchorzewski
CFO and Director of Med-X, Inc. since its inception, Ron Tchorzewski boasts more than 35 years of experience in financial accounting for start-up and development companies, as well as reporting for publicly held companies from Silicon Valley and beyond. As Chief Financial Officer, his purview includes business plan development, capital structure, and day-to-day accounting, and he positions Med-X, Inc. for financial success.
Jennifer Mills
Jennifer Mills is the President, Director, and Corporate Secretary of Med-X, Inc. She has worked for multiple companies in her career as a high-level accounting liaison, as well as in Human Resources and project management.
Nick Phillips
Nick Phillips began his career in the Hollywood entertainment world before moving into digital marketing for multiple products in Los Angeles. Now, he drives the Media Divisions at Med-X, Inc. His skill set, coupled with his dedication and attention to detail, ensures solid leadership for our Media and E-Commerce Divisions.
Dr. Allan Kurtz
Dr. Allan Kurtz is board-certified in internal medicine and has owned and operated a professional medical corporation, since 1986. Dr. Kurtz has been the Medical Director of both the Warner Medical Center and the California Center of Longevity and Functional Medicine. He is also a long-time member of the American Osteopathic College of Internal Medicine.
Dr. Morton Hyson
Dr. Morton Hyson is in private practice as a Board-certified Neurologist in Las Vegas, Nevada. He is also a Clinical Assistant Professor at Touro University in San Francisco, California, where he has been educating since September 2000. His professional affiliations include the American Medical Association, the American Academy of Neurology, the American Academy of Neurological and Orthopedic Surgeons, and the American Headache Society.
Frederick Dashiell, Jr.
Frederick Dashiell, Jr. has held various teaching positions at educational institutions such as Chapman University, California Institute of Technology, and University of California, Los Angeles. He has also held computer scientist and research scientist positions in the private sector. Mr. Dashiell received a Bachelor of Science in Physics from the University of North Carolina at Chapel Hill in 1963 and a Ph.D. in Mathematics from the University of California, Berkeley in 1973.
Updates
04/15/2022
NEW: Med-X Closing Regulation A+ Offering on April 22nd, 2022
In this important video update, CEO, Matthew Mills discusses how the company will be ending its Regulation A+ crowdfunding initiative. On April 22nd, 2022 at 11:59PM PST, Med-X, Inc. investor platform “www.medxinvestor.com” will be closed and no longer be available for investors to participate in the Company’s crowdfunding efforts. Please watch the video to find out details about the offering closing and more.
12/07/2021
Med-X Engages with Investor Relations Group, MZ North America as Planning to Access the Awaiting $100MM in Capital from Global Emerging Markets Continues
In this company update, CEO, Matthew Mills informs the shareholders on the new relationship with Investor Relations Firm MZ North America. Matthew informs the shareholders on the company's continued focus to gain access to the $100 Million in capital from GEM. Matthew also discusses changes to the Board of Directors as well as an update on international sales and marketing opportunities.
11/03/2021
Med-X, Inc. Receives Patent on Nature-Cide Insecticidal Soil
LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Med-X, Inc. (Med-X) announced that in October 2021 the Company received Patent No. 11,147,266 B2 for its Nature-Cide Insecticidal Soil formulation. What started as a soil application for the cannabis industry in 2016 has blossomed into a multi-use soil blend for all types of cultivation, from greenhouse and agricultural applications to cannabis/hemp operations.
10/01/2021
Med-X, Inc. Relaunches its Regulation A+ Crowdfunding Offering in Preparation for a Public Market Listing to Access its $100 Million Capital Commitment
In this very important video update COO and President, Matthew Mills informs the shareholders on the positioning and the preparation to list the Company on a national exchange to access the $100 million capital commitment for expansion that's waiting in the open market for the Company. Matthew is actively engaging in discussions with the investment banking community to help support our efforts to make this goal a reality.
Please watch the video and read the formal press release below.
08/09/2021
Med-X, Inc. Secures $100 Million Expansion Capital Commitment from Global Emerging Markets (GEM)
LOS ANGELES, Aug. 6, 2021 /PRNewswire/ -- Today, Med-X, Inc. (MED-X) announced a $100 million capital commitment from GEM Global Yield, LLC SCS (GGY), a Luxembourg-based private alternative investment group. Under the agreement, GGY will provide MED-X with a Share Subscription Facility of up to $100 million for a 36-month term following the public listing of MED-X's common stock.
Med-X will control the timing and maximum number of drawdowns and under this agreement can put a drawdown notice for up to $10MM worth of shares on the first day of trading. Concurrent with a public listing Med-X will issue warrants to GEM to purchase up to 4.0% of the common stock of the company. Med-X's flagship division, Nature-Cide, has developed a line of all-natural professional pest control applications. One of its pest control solutions for Vector Control, is continuously being tested by third parties with astounding recorded results. The products are set for expansion, from major distribution partners in in various regions around the globe.
"GEM's equity investment solidifies our business model as well as our long-term financial goals while reinforcing and furthering our mission to the world stage", states founder and COO Matthew Mills. "So far, we've been very successful with self-underwriting our Regulation A+ Offering, which has generated investments from more than 3,600 individuals over the last 4 years. This new $100MM capital commitment should allow the Company to advance on its Mergers & Acquisitions strategy, while propelling the brands in a manner where our mission of "Making a difference every day" will move to a whole new level", states Mills.
About Med-X, Inc.
Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Thermal-Aid and Malibu Brands divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand.
For more information regarding Med-X, Inc., please visit www.medx-rx.com, email info@medx-rx.com or call 818-349-2870
About The GEM Global Yield, LLC SCS Group
About GEM
Global Emerging Markets ('GEM') is a $3.4 billion, alternative investment group with offices in Paris, New York and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 440 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities, and select venture investments. For more information: https://www.gemny.com
GEM Contact:
Jean-Luc Bonnefoy: jbonnefoy@gemny.com
Med-X Contact
Matthew Mills: matt@medx-rx.com
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the Regulation A+ Offering Circular Securities Exchange Commission filings before making any investment in the Company.
This article may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.
SOURCE Med-X, Inc.
